The Broad Institute, Inc.;The Brigham and Women's Hospital, Inc.;Massachusetts Institute of Technology
发明人:
Aviv Regev,Ana C. Anderson,Vijay K. Kuchroo,Sema Kurtulus,Asaf Madi
申请号：
US16630887
公开号：
US20200149009A1
申请日:
2018.07.13
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The subject matter disclosed herein is generally directed to novel CD8+ tumor infiltrating lymphocyte (TIL) subtypes associated with response to immunotherapy treatment. Specifically, the subtypes are associated with checkpoint blockade therapy. Moreover, the subject matter disclosed herein is generally directed to methods and compositions for use of the subtypes. Also, disclosed herein are gene signatures and markers associated with the subtypes and use of said signatures and markers. Further disclosed are therapeutic methods of using said gene signatures and immune cell subtypes. Further disclosed are pharmaceutical compositions comprising populations of CD8+ TILs enriched for a specific subtype.
